Latest Breaking News On - Lepu biopharma - Page 1 : comparemela.com

US-based Zenas BioPharma closes upsized Series C round at $200m

US-based Zenas BioPharma closes upsized Series C round at $200m
dealstreetasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dealstreetasia.com Daily Mail and Mail on Sunday newspapers.

New zealand generalNew zealandUnited statesZenas biopharmaTellus bioventuresJack nunnLepu biopharmaTim xiaoEnavate sciencesAbraxis bioscienceEisai corporationEnterprise associatesQuan venture fundNew enterprise associatesNorwest venture partnersDelos capital

Checkpoint Inhibitors Clinical Trial Pipeline Insights | 180+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space |

Checkpoint Inhibitors Clinical Trial Pipeline Insights | 180+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space |
medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.

Sandeep joshiImmuneonco biopharmaAkeso biopharmaSerono merckLyvgen biopharmaMereo biopharmaTheravance biopharmaEucure biopharmaBristol myers squibbInnovent biologicsLepu biopharmaMarket researchBoehringer ingelheimCanbas co ltdKey checkpoint inhibitors companiesSecarna pharmaceuticals gmbh co

Week In Review: $1 7B Collaboration Between Elpiscience And Astellas Is Final 2023 Deal

Week In Review: $1 7B Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesFrance generalJanssen pharmaLepu biopharmaGracell fasXuanzhu biopharmaQilu pharmaElpiscience biopharmaAstellas pharmaSanegene bioInnovent biologicsFingerprint identification securityBispecific macrophage engager platformTumor associated macrophageSuzhou san diego

Biocytogen and CtM Bio Achieve Milestone Progress in Co-Developing a TCR-mimic Antibody-based Multi-Specific T Cell Engager Targeting WT1/HLA-A02

BEIJING & SHANGHAI Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and CtM Biotech (Shanghai) Co., Ltd (“CtM Bio”) today jointly…

United statesSan franciscoLei fangNew yorkBarbara shecterLepu biopharmaYuelei shenGabriel friedmanHaimen jiangsuTed rechtshtaffenJoe oconnorCanada revenue agencyCtm biotech shanghai co ltd bioCtm bio achieve milestone progress in coNational postBiocytogen pharmaceuticals beijing co ltd

Healthcare-focused Vivo Capital closes new RMB fund at $1 4b

Vivo Capital closed the new RMB fund about 19 months after a first close at 4 billion yuan ($559.8 million) in May 2022.

United statesT ai peiPalo altoShan fuHong kongLepu biopharmaVivo suzhou health industry investment fundVivo capitalHealth industry investment fundGreater chinaWuxi apptec